M&A

Backed by activist investor Irenic Capital, a new $220M blank-check firm hits Nasdaq, aiming to acquire a target in the aerospace or industrial sectors.

Just seven years after its founding, IEQ Capital sees four founders named to Forbes' elite list. Here's how they built a $42 billion wealth powerhouse.

Western Metallica's deal with Emerita expires, but a crucial three-year permit renewal for its Nueva Celti copper project signals a strategic reset.

Christopher Kilpatrick's 2026 departure from Western Asset's HIX fund is part of a larger strategic personnel shift at parent company Franklin Templeton.

The struggling footwear brand is selling its assets to become NewBird AI, a GPU provider. Is it a visionary gamble or a desperate move in the AI gold rush?

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

Transom Capital Group appoints Luke Dauch, a decade-long J.P. Morgan banker, to bolster its deal origination in a competitive middle-market landscape.

Following a massive stock surge, Forte Biosciences is raising $150M. The funds are crucial for a pivotal year of clinical trials for its autoimmune drug.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

The oil producer's new BBB- ratings signal deep financial strength, unlocking lower borrowing costs, enhanced strategic options, and greater shareholder value.

Despite a revenue dip, Kelyniam Global slashed its net loss, secured FDA clearance for a breakthrough implant, and rejected a buyout, charting its own course.

Kestrel Group reports soaring fee income from its core business, but a quarterly loss reveals the deep financial drag from its complex merger with Maiden Holdings.

The European FinTech giant plans a new €70M note issue and a tender offer to refinance debt, signaling a major push for financial flexibility and expansion.

With $336M in the bank and three autoimmune drugs advancing, Jade Biosciences lays out a fast-paced timeline for key clinical milestones in 2026 and 2027.

Denver M&A firm SDR Ventures promotes veteran advisor Scott Mitchell, doubling down on its client-centric strategy for entrepreneurs in a competitive market.

Palmer Square Capital BDC reports a drop in 2025 income and asset value but highlights rock-solid credit quality and an optimistic outlook for 2026.

After a massive divestiture, Vistance Networks reports soaring growth, zero debt, and plans a huge special cash distribution to its shareholders.

EPIC Insurance creates a new leadership role for Miranda Rodriguez, a strategic move to scale its real estate practice and challenge market leaders.

Thermon Group's $2.2 billion sale to CECO Environmental faces legal scrutiny, leaving shareholders to question if the offer is fair amid record profits.